Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study.
A high consumption of trans fatty acids (TFAs) is associated with an increased risk of cardiovascular diseases (CVDs). High-density lipoproteins (HDLs) have many cardioprotective properties and transport functional microRNAs (miRNAs) to recipient cells. We hypothesized that dietary TFAs modify the HDL-carried miRNA profile, therefore modulating its cardioprotective properties. We assessed whether consumption of dietary TFAs modifies HDL-carried miR-223-3p and miR-135a-3p concentration and the inter-relationship between diet-induced changes in HDL-carried miRNA concentration and CVD risk markers. In a double blind, randomized, crossover, controlled study, 9 men were fed each of 3 experimental isoenergetic diets: 1) High in industrial TFA (iTFA; 3.7% energy); 2) High in TFA from ruminants (rTFA; 3.7% energy); 3) Low in TFA (control; 0.8% energy) for 4 weeks each. HDLs were isolated by ultracentrifugation and miRNAs were quantified by RT-qPCR. Variations in HDL-miR-223-3p concentration were negatively correlated with variations in HDL-cholesterol after the iTFA diet (rs = 0.82; P = 0.007), and positively correlated with variations in C-reactive protein concentration after the rTFA diet (rs = 0.75; P = 0.020). Variations in HDL-miR-135a-3p concentration were positively correlated with variations in total triglyceride (TG) concentration following the iTFA diet (rs = -0.82; P = 0.007), and with variations in low-density lipoprotein (LDL)-TG concentration following the rTFA diet (rs = 0.83; P = 0.005), compared to the control diet. However, the consumption of dietary TFAs has no significant unidirectional impact on HDL-carried miR-223-3p and miR-135a-3p concentrations. Our results suggest that the variability in the HDL-carried miRNAs response to TFA intake, by being associated with variations in CVD risk factors, might reflect physiological changes in HDL functions.
a Département de biochimie , Université de Sherbrooke , Sherbrooke , Québec , Canada.|b Centre de recherche clinique ECOGENE-21, CIUSSS du Saguenay-Lac-St-Jean , Saguenay , Québec , Canada.
Véronique
V
Desgagné
a Département de biochimie , Université de Sherbrooke , Sherbrooke , Québec , Canada.|b Centre de recherche clinique ECOGENE-21, CIUSSS du Saguenay-Lac-St-Jean , Saguenay , Québec , Canada.
Simon-Pierre
SP
Guay
c Département de biologie médicale , CIUSSS du Saguenay-Lac-St-Jean , Saguenay , Québec , Canada.
Renée
R
Guérin
a Département de biochimie , Université de Sherbrooke , Sherbrooke , Québec , Canada.
François
F
Corbin
d Institute of Nutrition and Functional Foods (INAF), Université Laval , Québec , Canada.
Patrick
P
Couture
d Institute of Nutrition and Functional Foods (INAF), Université Laval , Québec , Canada.
Benoit
B
Lamarche
a Département de biochimie , Université de Sherbrooke , Sherbrooke , Québec , Canada.|b Centre de recherche clinique ECOGENE-21, CIUSSS du Saguenay-Lac-St-Jean , Saguenay , Québec , Canada.
Luigi
L
Bouchard
D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D004032:Diet; D004311:Double-Blind Method; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D044242:Trans Fatty Acids / Q000008:administration & dosage / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D002097:C-Reactive Protein; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D035683:MicroRNAs; D044242:Trans Fatty Acids; D014280:Triglycerides; C544965:MIRN135 microRNA, human; C525067:MIR223, human
Blood miRNA; CVD; HDL; TFA; microRNA